Abstract
With the development of organoid culture methods, it is now possible to culture organoids for a variety of cancer types. Cancer organoids are culture models that retain the characteristics of patient cancer, especially plasticity and diversity. Because organoid culture can now be performed from a patient’s tumor in a short time and has shown a high success rate in some cancer types, it is expected to be used not only in personalized medicine to select the best treatment for each patient, but also in drug discovery, including screening and biomarker development. As a means of assessing the response of cancer cells, it is expected to be used as a complement to the snapshot-like information such as genomics information. This paper describes the current application of cancer organoid culture to pharmaceutical research and presents issues that need to be resolved.
